This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


New Research Estimates MRSA Infections Cost U.S. Hospitals $3.2 Billion to $4.2 Billion Annually


WASHINGTON, D.C. -- The annual nationwide cost to treat hospitalized patients with methicillin-resistant Staphylococcus aureus (MRSA) infections is estimated to be between $3.2 billion to $4.2 billion, according to a new analysis presented at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The high costs of treating infections caused by MRSA, a serious, multi-drug resistant-pathogen, are primarily driven by prolonged hospital stays, including time spent in intensive care units.(1)  Previous data showed that patients with MRSA infections may be in the hospital 10 days longer than patients with Staph infections not resistant to methicillin. 


“MRSA is acknowledged as a growing problem, but the associated medical costs are not well documented.  This research helps to quantify the significant economic burden of MRSA to U.S. hospitals," says Larry Liu, MD, PhD, lead investigator and director of U.S. Outcomes Research Group at Pfizer Inc.  "Strategies to minimize hospital costs related to MRSA infections need to be considered to help manage this burden."


« Previous123Next »
comments powered by Disqus